Skip to main content
. 2006 Mar 9;116(4):1025–1036. doi: 10.1172/JCI23792

Figure 6. The anti-CD137 mAb–mediated therapeutic effect depends partly on CD8+ T cells and IFN-γ.

Figure 6

(A) CD8+ T cell depletion and (B) anti–IFN-γ mAb application significantly increased AHR (measured on day 18) in anti-CD137 mAb–treated OVA-immunized BALB/c mice compared with control mice. (C) Depletion of CD8+ T cells and (D) application of anti–IFN-γ mAb before anti-CD137 mAb treatment increased the total cell number and the number of eosinophils in BAL fluid of anti-CD137–treated OVA-immunized mice. (E) Depletion of CD8+ T cells and (F) application of anti–IFN-γ mAb had no effect on the decreased levels of Th2 cytokines after anti-CD137 mAb treatment, whereas the CD137-mediated increase in IFN-γ production was abrogated. *P < 0.05, OVA plus anti-CD137 mAb versus OVA plus anti-CD137 mAb plus anti-CD8 mAb; ***P < 0.001, OVA plus anti-CD137 mAb versus OVA plus anti-CD137 mAb plus anti–IFN-γ mAb by Student’s t test. (a–d) Data are expressed as mean ± SEM; n ≥ 9 animals per group and data point for 3 independent experiments. (E and F) Data are expressed as mean ± SEM; n ≥ 4 animals for each group, and representative results from 1 of 3 experiments are shown.